Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.
Agile Therapeutics (AGRX) closed at $1.86 in the latest trading session, marking no change from the prior day.
Agile Therapeutics is currently trading substantially below its fair value of $6.36/shr on a stand-alone basis.Agile's leading drug, Twirla, is much more valuable in the hands of a Big Pharma company, like J&J, who has the resources and footprint to maximize …
Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company’s Lead Product Candidate, Receives FDA Approval.
Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $45 million. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
PRINCETON, N.J., Feb. 25, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the Company will visit the Nasdaq.
NEW YORK, May 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, AGRX, CGC, FLDM, and CAPR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selec…
What happened Agile Therapeutics (NASDAQ: AGRX), a small-cap women's healthcare company, is starting the week off on the right foot. Specifically, the drugmaker's shares are up by 11.2% on extremely heavy volume, as of 10:40 a.
Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
NEW YORK, May 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, AGRX, CGC, FLDM, and CAPR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selec…
Is (AGRX) Outperforming Other Medical Stocks This Year?
“At the beginning of the COVID-19 pandemic, we took proactive steps by moving all employees to work from home settings for their health and safety, while pursuing business continuity during this pivotal time in the Company’s history,” said Al Altomari, Chairman and Chief Executive Officer of Agile. With respect to our manufacturing process, we have completed production of the pre-validation batch and subject to final quality control testing that we expect to be completed soon, we will transition into the final validation phase.
Cheap stocks - that is, really cheap stocks that trade for single-digit prices - are among the most divisive stocks on Wall Street.Some investors tend to avoid these names entirely. While nominal prices typically don't matter (there's little difference between a $50 stock and a $500 stock), stocks under $10 are different. They often face some sort of difficulty, such as weak fundamentals or overwhelming headwinds. Also, institutional buyers such as pensions and hedge funds often won't buy stocks that are cheaper than $10, and they really become sparse under the $5 mark. Thus, these companies miss out on the steadiness that accompanies institutional ownership.But other investors love cheap stocks. In many cases, they see opportunity in these often battered shares, and some people simply prefer to buy their stocks in "lots" (typically 100 shares at a time) - something that's a little more difficult to do with the triple- and quadruple-digit crowd.The reality is, low-priced stocks are a mix of high-return opportunity but also high risk. The crazy volatility introduced by the coronavirus outbreak certainly doesn't help. Further complicating things is that many of them are largely ignored by the media, making information difficult to come by. So if you are going to take a moonshot, take a cue from the pros that routinely cover these companies.Here are seven of the best cheap stocks under $7. Using TipRanks' Stock Screener tool, we identified seven low-priced stocks that still have decent Wall Street analyst coverage and extremely bullish sentiment. Note that every one of these stocks still comes with colossal risk. But if you're looking to get aggressive and buy cheap on dips, the pros think each of these can offer some promise. SEE ALSO: 13 Super Small-Cap Stocks to Buy for 2020 and Beyond
Over the last month, shares of micro-cap biotech Agile Therapeutics (AGRX) have crashed by an alarming 55%. Following such a remarkable decline, you would think the company must be in real trouble, but not so, says one analyst.Maxim’s Jason McCarthy argues that not only does the pullback set up an “attractive entry point,” if you take a deeper look at the company’s finances and catalysts, there’s a very attractive opportunity at play.Although volatility currently reigns supreme across the board, since the turn of the year, AGRX has been on a unique rollercoaster ride. Less than six weeks ago, Agile’s share price was on the rise following the FDA’s approval of Twirla, the company’s contraceptive patch. As it stands, the plan to launch Twirla in Q4 still remains on track. So far, there have been no delays from manufacturing partner Corium.Additionally, McCarthy notes, after recent measures, Agile has a very healthy balance sheet. In February, Agile secured a loan deal from Perceptive Advisors, for $35 million, which is interest free until 2023. Also last month, Agile raised an additional $48 million from equity financing.McCarthy said, “YE-19 cash was $34.5M. Remember, that alone would have likely gotten the company through 2020. However, when we combine the loan from Perceptive, use of the ATM and the $48M in net proceeds from the 2/21 equity financing, Agile should have ~$100M in cash. With Twirla launching later this year, there should be at least 2 years of runway, possibly longer depending on the launch trajectory.”Based on the combination of an approved drug, a strong balance sheet and favorable timelines to “weather the COVID-19 storm,” the analyst rates Agile as a “top pick in our coverage universe.”Therefore, McCarthy reiterates a Buy rating on Agile along with a $8 price target. The implication for investors? Possible upside of a sky scraping 406%. (To watch McCarthy’s track record, click here)The Street agrees. Agile’s Strong Buy consensus rating breaks down into solely Buy ratings – 5, in fact. The average price target comes in identical to McCarthy’s, at $8.00. (See Agile stock analysis on TipRanks)
Q1 2020 Agile Therapeutics Inc Earnings Call
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
Q1 2020 Agile Therapeutics Inc Earnings Call
Recent buys from company CFOs Continue reading...
Agile Therapeutics, Inc. (AGRX), a forward-thinking women’s healthcare company, today announced it will report first quarter 2020 financial results after the market close on Tuesday, May 5, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update. Investors interested in listening to the conference call may do so by dialing (877) 407-2991 for domestic callers or (201) 389-0925 for international callers.
Agile Therapeutics, Inc. (AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon Barbari for election as a class III director to replace Abhijeet Lele, a member of the company’s board of directors and the board’s Lead Independent Director, who will not stand for re-election and cease to be a director on June 9, 2020, the date of the company’s Annual Meeting of Stockholders. In addition, William McKee has informed the company that he will retire from the company’s board of directors effective June 9, 2020.
Agile Therapeutics (AGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
PRINCETON, N.J., May 11, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer,.
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.